Logo image of EFTR

EFFECTOR THERAPEUTICS INC (EFTR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EFTR - US28202V2079 - Common Stock

0.18 USD
-0.09 (-32.56%)
Last: 7/2/2024, 8:16:09 PM
0.155 USD
-0.02 (-13.89%)
After Hours: 7/2/2024, 8:16:09 PM
Fundamental Rating

2

EFTR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. The financial health of EFTR is average, but there are quite some concerns on its profitability. EFTR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EFTR had negative earnings in the past year.
In the past year EFTR has reported a negative cash flow from operations.
In multiple years EFTR reported negative net income over the last 5 years.
In the past 5 years EFTR reported 4 times negative operating cash flow.
EFTR Yearly Net Income VS EBIT VS OCF VS FCFEFTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 10M -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -127.64%, EFTR is not doing good in the industry: 83.39% of the companies in the same industry are doing better.
EFTR has a worse Return On Equity (-4187.55%) than 84.27% of its industry peers.
Industry RankSector Rank
ROA -127.64%
ROE -4187.55%
ROIC N/A
ROA(3y)-74.35%
ROA(5y)-100.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EFTR Yearly ROA, ROE, ROICEFTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 400 -400 600 -600

1.3 Margins

EFTR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EFTR Yearly Profit, Operating, Gross MarginsEFTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 1K -1K -2K

More info and screens

4

2. Health

2.1 Basic Checks

EFTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EFTR has more shares outstanding
EFTR has a worse debt/assets ratio than last year.
EFTR Yearly Shares OutstandingEFTR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
EFTR Yearly Total Debt VS Total AssetsEFTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -13.64, we must say that EFTR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EFTR (-13.64) is worse than 83.57% of its industry peers.
EFTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.64
ROIC/WACCN/A
WACC7.97%
EFTR Yearly LT Debt VS Equity VS FCFEFTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 1.03 indicates that EFTR should not have too much problems paying its short term obligations.
EFTR's Current ratio of 1.03 is on the low side compared to the rest of the industry. EFTR is outperformed by 88.46% of its industry peers.
EFTR has a Quick Ratio of 1.03. This is a normal value and indicates that EFTR is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.03, EFTR is not doing good in the industry: 86.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
EFTR Yearly Current Assets VS Current LiabilitesEFTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

EFTR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.92%.
EFTR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-9.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.92% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.09%
EPS Next 2Y36.54%
EPS Next 3Y24.92%
EPS Next 5Y14.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EFTR Yearly Revenue VS EstimatesEFTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 100M 200M 300M 400M
EFTR Yearly EPS VS EstimatesEFTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EFTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EFTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EFTR Price Earnings VS Forward Price EarningsEFTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EFTR Per share dataEFTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as EFTR's earnings are expected to grow with 24.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3Y24.92%

More info and screens

0

5. Dividend

5.1 Amount

EFTR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EFFECTOR THERAPEUTICS INC

NASDAQ:EFTR (7/2/2024, 8:16:09 PM)

After market: 0.155 -0.02 (-13.89%)

0.18

-0.09 (-32.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2024-05-09/amc
Earnings (Next)08-06 2024-08-06/amc
Inst Owners5.71%
Inst Owner Change0%
Ins Owners89.77%
Ins Owner Change0%
Market Cap846.00K
Revenue(TTM)N/A
Net Income(TTM)-34.63M
Analysts85
Price Target11.22 (6133.33%)
Short Float %0.13%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.51%
Min EPS beat(2)-103.21%
Max EPS beat(2)2.19%
EPS beat(4)2
Avg EPS beat(4)-22.16%
Min EPS beat(4)-103.21%
Max EPS beat(4)15.72%
EPS beat(8)3
Avg EPS beat(8)-20.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-51.11%
EPS NQ rev (1m)-16.43%
EPS NQ rev (3m)-20.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-13.08
EYN/A
EPS(NY)-2.29
Fwd EYN/A
FCF(TTM)-6.23
FCFYN/A
OCF(TTM)-6.21
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.64%
ROE -4187.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.35%
ROA(5y)-100.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 75.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z -13.64
F-Score4
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)208.22%
Cap/Depr(5y)144.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y66.09%
EPS Next 2Y36.54%
EPS Next 3Y24.92%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.62%
OCF growth 3YN/A
OCF growth 5YN/A

EFFECTOR THERAPEUTICS INC / EFTR FAQ

What is the fundamental rating for EFTR stock?

ChartMill assigns a fundamental rating of 2 / 10 to EFTR.


What is the valuation status of EFFECTOR THERAPEUTICS INC (EFTR) stock?

ChartMill assigns a valuation rating of 1 / 10 to EFFECTOR THERAPEUTICS INC (EFTR). This can be considered as Overvalued.


What is the profitability of EFTR stock?

EFFECTOR THERAPEUTICS INC (EFTR) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for EFTR stock?

The Earnings per Share (EPS) of EFFECTOR THERAPEUTICS INC (EFTR) is expected to grow by 66.09% in the next year.